###begin article-title 0
###xml 28 29 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
Potential Relevance of alpha1-Adrenergic Receptor Autoantibodies in Refractory Hypertension
###end article-title 0
###begin p 1
Conceived and designed the experiments: KW HH GW DNM FCL RD RD PK. Performed the experiments: KW HH GW WD SB VH FH NH HS MJ CL CS SV RD PK. Analyzed the data: KW HH WD SB VH FH NH HS SV IM DNM FCL RD RD PK. Contributed reagents/materials/analysis tools: KW HH GW WD SB IM PK. Wrote the paper: KW HH FCL RD PK.
###end p 1
###begin p 2
These authors also contributed equally to this work.
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 46 47 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 74 75 66 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 161 162 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Agonistic autoantibodies directed at the alpha1-adrenergic receptor (alpha1-AAB) have been described in patients with hypertension. We implied earlier that alpha1-AAB might have a mechanistic role and could represent a therapeutic target.
###end p 4
###begin title 5
Methodology/Principal Findings
###end title 5
###begin p 6
###xml 135 136 131 132 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 265 266 257 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 304 305 292 293 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 324 325 308 309 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 346 347 326 327 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 615 617 591 593 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1A</sub>
###xml 671 672 643 644 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 693 694 661 662 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 882 890 850 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLA2-IIA</italic>
###xml 920 927 888 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cacna1c</italic>
###xml 1056 1057 1020 1021 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1078 1079 1038 1039 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1274 1276 1234 1236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
###xml 225 232 <span type="species:ncbi:9986">Rabbits</span>
###xml 311 318 <span type="species:ncbi:9606">Patient</span>
###xml 334 340 <span type="species:ncbi:9986">rabbit</span>
###xml 490 493 <span type="species:ncbi:10116">rat</span>
###xml 510 513 <span type="species:ncbi:10116">rat</span>
###xml 555 570 <span type="species:ncbi:10029">Chinese hamster</span>
###xml 604 609 <span type="species:ncbi:9606">human</span>
###xml 658 665 <span type="species:ncbi:9606">patient</span>
###xml 681 687 <span type="species:ncbi:9986">rabbit</span>
###xml 1043 1050 <span type="species:ncbi:9606">patient</span>
###xml 1066 1072 <span type="species:ncbi:9986">rabbit</span>
To pursue the issue, we performed clinical and basic studies. We observed that 41 of 81 patients with refractory hypertension had alpha1-AAB; after immunoadsorption blood pressure was significantly reduced in these patients. Rabbits were immunized to generate alpha1-adrenergic receptor antibodies (alpha1-AB). Patient alpha1-AAB and rabbit alpha1-AB were purified using affinity chromatography and characterized both by epitope mapping and surface plasmon resonance measurements. Neonatal rat cardiomyocytes, rat vascular smooth muscle cells (VSMC), and Chinese hamster ovary cells transfected with the human alpha1A-adrenergic receptor were incubated with patient alpha1-AAB and rabbit alpha1-AB and the activation of signal transduction pathways was investigated by Western blot, confocal laser scanning microscopy, and gene expression. We found that phospholipase A2 group IIA (PLA2-IIA) and L-type calcium channel (Cacna1c) genes were upregulated in cardiomyocytes and VSMC after stimulation with both purified antibodies. We showed that patient alpha1-AAB and rabbit alpha1-AB result in protein kinase C alpha activation and transient extracellular-related kinase (EKR1/2) phosphorylation. Finally, we showed that the antibodies exert acute effects on intracellular Ca2+ in cardiomyocytes and induce mesentery artery segment contraction.
###end p 6
###begin title 7
Conclusions/Significance
###end title 7
###begin p 8
###xml 13 14 9 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 35 36 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 191 192 179 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
###xml 23 29 <span type="species:ncbi:9986">rabbit</span>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
Patient alpha1-AAB and rabbit alpha1-AB can induce signaling pathways important for hypertension and cardiac remodeling. Our data provide evidence for a potential clinical relevance for alpha1-AAB in hypertensive patients, and the notion of immunity as a possible cause of hypertension.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 173 176 173 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Antonelli1">[1]</xref>
###xml 178 181 178 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Rapoport1">[2]</xref>
###xml 344 347 344 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Dragun1">[3]</xref>
###xml 349 352 349 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Wallukat1">[4]</xref>
###xml 444 445 441 442 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 578 581 575 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Jahns1">[5]</xref>
###xml 493 501 <span type="species:ncbi:9606">patients</span>
###xml 539 542 <span type="species:ncbi:10116">rat</span>
Autoimmunity with agonistic autoantibodies directed at endogenous receptors can cause Graves' disease through the thyrotropin receptor and promotes insulin release via CD38 [1], [2]. Agonistic antibodies that stimulate the angiotensin (Ang) II AT1 receptor have been described in preeclampsia and humorally mediated kidney transplant rejection [3], [4]. The most compelling case for agonistic autoantibody-mediated disease has been that of beta1-adrenergic receptor autoantibodies observed in patients with dilated cardiomyopathy and in a rat model fulfilling Koch's postulates [5]. However, autoantibodies could also merely be an epiphenomenon in many instances; convincing data are still pending.
###end p 10
###begin p 11
###xml 5 6 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 33 34 25 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 191 194 183 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Piascik1">[6]</xref>
###xml 201 202 189 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 345 348 333 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Michelotti1">[7]</xref>
###xml 449 450 433 434 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 489 490 469 470 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 546 547 522 523 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 724 727 700 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Barzilay1">[8]</xref>
###xml 794 797 770 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Shannon1">[9]</xref>
###xml 864 865 836 837 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 916 917 884 885 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1023 1025 987 989 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1A</sub>
###xml 1165 1169 1129 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Huang1">[10]</xref>
###xml 1186 1187 1146 1147 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1373 1375 1329 1331 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1A</sub>
###xml 1428 1432 1384 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-OConnell1">[11]</xref>
###xml 1434 1438 1390 1394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-OConnell2">[12]</xref>
###xml 1204 1208 <span type="species:ncbi:10090">mice</span>
alpha1-adrenergic receptor (alpha1-AR) signaling mediates several cardiovascular actions such as vascular smooth muscle cell (VSMC) contraction, cardiac inotropy, hypertrophy, and remodeling [6]. alpha1-AR are predominantly located postsynaptically on VSMC, where they are the targets of circulating norepinephrine and regulate VSMC contraction [7]. Sympathetic over-activity in hypertension and accompanying excess stimulation of postsynaptic alpha1-AR supports the use of selective alpha1-AR inhibitors as antihypertensive drugs. However, alpha1-AR blockade was discontinued in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) because of a putative increased risk for heart failure [8], a highly controversial decision that has been sharply criticized [9]. The Valsartan Heart Failure Trial 2 (Val-HeFT2) showed that alpha1-AR blockade was beneficial in heart failure. alpha1-AR can contribute to cardiomyocyte hypertrophy. Huang et al demonstrated a protective effect of the alpha1A-AR-subtype in cardiac myocytes and defined an extracellular-regulated kinase (ERK) signaling pathway that is required for myocyte survival [10]. Hearts of alpha1-AR gene-deleted mice had increased interstitial fibrosis, increased apoptosis, and failed induction of the fetal hypertrophic gene program after pressure overload, indicating that alpha1A-AR are required for myocardial adaptation to stress [11], [12].
###end p 11
###begin p 12
###xml 60 61 56 57 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 84 85 76 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 89 93 81 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Fu1">[13]</xref>
###xml 95 99 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Liao1">[14]</xref>
###xml 101 105 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Luther1">[15]</xref>
###xml 205 206 193 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 218 222 206 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Luther1">[15]</xref>
###xml 289 290 273 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 352 353 332 333 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 365 369 345 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Zhou1">[16]</xref>
###xml 395 396 371 372 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 417 418 389 390 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 479 480 447 448 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 629 630 593 594 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 665 666 625 626 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 747 748 703 704 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 784 785 736 737 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 811 812 759 760 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 939 940 883 884 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 959 960 899 900 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1093 1094 1029 1030 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1113 1114 1045 1046 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1333 1334 1257 1258 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1468 1469 1388 1389 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
###xml 318 322 <span type="species:ncbi:10116">rats</span>
###xml 375 379 <span type="species:ncbi:10116">rats</span>
###xml 755 761 <span type="species:ncbi:9986">rabbit</span>
###xml 794 801 <span type="species:ncbi:9986">rabbits</span>
###xml 822 830 <span type="species:ncbi:9606">patients</span>
###xml 927 933 <span type="species:ncbi:9986">rabbit</span>
###xml 948 953 <span type="species:ncbi:9606">human</span>
###xml 1081 1087 <span type="species:ncbi:9986">rabbit</span>
###xml 1102 1107 <span type="species:ncbi:9606">human</span>
###xml 1322 1327 <span type="species:ncbi:9606">human</span>
Others and we have described agonistic autoantibodies (alpha1-AAB) against the alpha1-AR [13], [14], [15]. Earlier, we examined immunoglobulin fractions in 54 severely hypertensive patients and found alpha1-AAB in 44% [15]. However, 12% of normotensive control subjects also harbored alpha1-AAB. Zhou et al. immunized rats with a peptide from the alpha1-AR epitope [16]. The rats developed alpha1-AR antibodies (alpha1-AB) and cardiac hypertrophy. However, the link between alpha1-AB formation and cardiac remodeling remains unclear. We have now performed additional studies to elucidate the pathophysiological relevance of alpha1-AAB. We show that removal of alpha1-AAB with immunoadsorption is feasible and lowers blood pressure. We raised alpha1-AB in rabbit and purified the alpha1-AB from rabbits and alpha1-AAB from patients by affinity chromatography. After confirming binding and functional specificity of the isolated rabbit alpha1-AB and human alpha1-AAB, we performed gene expression analysis in cardiomyocytes and vascular smooth muscle cells (VSMC). We show that both rabbit alpha1-AB and human alpha1-AAB can evoke calcium signaling and contract vessel preparations via protein kinase C alpha (PKC-alpha) activation and transient extracellular-related kinase (ERK 1/2) phosphorylation. Our data suggest that human alpha1-AAB can induce signaling pathways involved in hypertension and cardiac remodeling, suggesting a potential clinical relevance of alpha1-AAB.
###end p 12
###begin title 13
Results
###end title 13
###begin p 14
###xml 17 18 13 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 307 308 297 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 516 517 502 503 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 585 592 571 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003742-t001">Table 1</xref>
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 185 192 <span type="species:ncbi:9606">patient</span>
###xml 278 286 <span type="species:ncbi:9606">patients</span>
###xml 531 539 <span type="species:ncbi:9606">patients</span>
###xml 545 552 <span type="species:ncbi:9606">patient</span>
We analyzed alpha1-AAB in 81 patients with refractory hypertension, who required >/=3 antihypertensive medications. Severe hypertension-induced target organ damage was present in every patient, including funduscopic changes, cardiac abnormalities, and kidney damage. Fourty-one patients (51%) featured alpha1-AAB as assessed by cardiomyocyte contraction assay. Microalbuminuria was detected in 33%, diastolic dysfunction in 87%, left ventricular (LV) hypertrophy in 85%, and reduced ejection fraction in 13% of alpha1-AAB positive patients. The patient characteristics are outlined in Table 1.
###end p 14
###begin title 15
###xml 53 54 49 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
Clinical features of the patients classified as alpha1-AR-AA positive or negative.
###end title 15
###begin p 16
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g001">Figure 1</xref>
###xml 39 40 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 213 214 205 206 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 277 289 269 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g001">Figure 1A, B</xref>
###xml 374 375 362 363 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 435 444 423 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g001">Figure 1C</xref>
###xml 687 696 675 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g001">Figure 1D</xref>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Figure 1 shows data from the five alpha1-AAB positive patients undergoing immunoadsorption. The treatments were performed daily for 5 days. The cardiomyocyte contraction assay documented gradually decreasing alpha1-AAB activity during the course of the five immunoadsorptions (Figure 1A, B). At the end of five days, the activity was in the normal range. The decreased alpha1-AAB activity persisted for the 180 day observation period (Figure 1C). Blood pressure recordings performed before and after 5 days of treatment showed a significant reduction in mean arterial pressure (MAP), compared to initial values that remained significantly reduced for the observation period of 180 days (Figure 1D).
###end p 16
###begin title 17
###xml 36 37 32 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
Effects of immunoadsorption on alpha1-AAB and blood pressure.
###end title 17
###begin p 18
###xml 159 160 155 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 141 148 <span type="species:ncbi:9606">patient</span>
###xml 424 432 <span type="species:ncbi:9606">patients</span>
###xml 472 479 <span type="species:ncbi:9606">patient</span>
(A) Ordinate shows neonatal cardiomyocyte spontaneous beating rate; abscissa shows response to immunoadorption performed on a representative patient. The alpha1-AAB activity decreased with every immunoadsorption with a total decrease in response over time. (B) Figure shows the initial spontaneous beating rate (closed circles). After five immunoadsorptions, this response is reduced to basal values (open circles) in all 5 patients. (C) Mean response of a representative patient in cardiomyocyte contraction assay over time to immunoadsorption is shown. (D) Mean arterial pressure (MAP) was measured 5 and 180 days after immunoadsorption. MAP was significantly reduced compared to before immunoadsorption.
###end p 18
###begin p 19
###xml 5 6 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 160 169 156 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g002">Figure 2A</xref>
###xml 244 246 236 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1A</sub>
###xml 291 306 283 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g002">Figure 2B and C</xref>
###xml 721 722 710 711 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 753 754 738 739 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 805 807 786 788 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1A</sub>
###xml 150 158 <span type="species:ncbi:9606">patients</span>
alpha1-AAB were directed against the first extracellular loop (eL1) in 24% and against the second extracellular loop (eL2) in 27% of the hypertensive patients (Figure 2A). Epitope mapping for the first and second extracellular loop of the alpha1A-AR by cardiac contraction assay is shown in Figure 2B and C. Overlapping peptide sequences were tested for competition in cardiac contraction assay. For extracellular loop 1 (eL1) the peptide sequence P1 (YWAFGR) diminished the spontaneous beating rate response completely. The peptide sequence P2 (APEDET) competed for the antibody extracellular loop 2 (eL2) effect. Since activating autoantibodies against the second loop have already been described for the AT1-R and beta1-AR receptor, we analyzed alpha1-AAB against the second extracellular loop of alpha1A-AR in this study.
###end p 19
###begin title 20
###xml 60 66 56 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#913;</sub>
Epitope mapping for extracellular loop 1 and loop 2 of alpha1Alpha-AR is given.
###end title 20
###begin p 21
###xml 9 10 5 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
(A) alpha1-AAB were directed against the first extracellular loop (eL1) in 24% and against the second extracellular loop (eL2) in 27% of the hypertensive patients. (B) The peptide sequence P1 (YWAFGR) and P2 (GRVFCNI) (partially) for eL1 were able to diminish the spontaneous beating rate response completely. (C) Epitope mapping for loop 2 is given for the following amino acid sequences: P1: GWRQPA, P2: APEDET, P3: TICQIN, P4: INEEPG, P5: GYVLFS. The sequence P2 (APEDET) was able to diminish the spontaneous beating rate response completely.
###end p 21
###begin p 22
###xml 17 18 13 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 127 129 119 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1A</sub>
###xml 303 311 295 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g003">Figure 3</xref>
###xml 463 464 439 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 644 645 616 617 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 650 659 622 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g003">Figure 3A</xref>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
We purified alpha1-AAB from patients by affinity chromatography using the peptide of the second extracellular loop of the alpha1A-AR. We then used surface plasmon resonance (SPR) measurements to determine the binding affinity and specificity of purified autoantibody fractions. Sensorgrams, depicted in Figure 3, demonstrate that the antibodies displayed a high binding affinity (Kdapproximately50 nM) to the biotinylated peptide corresponding to eL2 of the alpha1-AR immobilized to the SA-sensorchip. This affinity-purified antibody fraction also showed weak cross-reactivity with the biotinylated peptide corresponding to the eL1 of the alpha1-AR (Figure 3A). However, this binding was negligible compared to the strong eL2 interaction.
###end p 22
###begin title 23
###xml 47 48 43 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 69 70 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 34 41 <span type="species:ncbi:9606">patient</span>
###xml 57 63 <span type="species:ncbi:9986">rabbit</span>
Binding and agonistic activity of patient alpha1-AAB and rabbit alpha1-AB.
###end title 23
###begin p 24
###xml 73 74 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 145 147 137 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1A</sub>
###xml 281 282 269 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 351 352 335 336 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 563 564 543 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 692 693 664 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 294 301 <span type="species:ncbi:9606">patient</span>
###xml 339 345 <span type="species:ncbi:9986">rabbit</span>
###xml 422 427 <span type="species:ncbi:9606">human</span>
###xml 445 451 <span type="species:ncbi:9986">rabbit</span>
###xml 635 642 <span type="species:ncbi:9606">patient</span>
###xml 680 686 <span type="species:ncbi:9986">rabbit</span>
Surface plasmon resonance sensorgrams depicting antibody binding to alpha1-AR peptides (A and B). Biotinylated peptide corresponding to the alpha1A-AR extracellular loop2 (eL2) were immobilized. A corresponding peptide to extracellular loop1 (eL1) served as negative control. alpha1-AAB from a patient with refractory hypertension (A) and rabbit alpha1-AB (B) bind exclusively to eL2. Note that the characteristics of the human antibody (A) and rabbit antibody (B) were the same. (C) Functional effects (cardiomyocyte contraction assay) of affinity-purified alpha1-AAB (0.1-1 microg/ml medium) against second extracellular loop from a patient with refractory hypertension and (D) rabbit alpha1-AB (0.12-1.2 microg/ml medium) against second extracellular loop. The functional findings corroborate the BIAcor results.
###end p 24
###begin p 25
###xml 84 85 80 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 102 103 94 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 218 219 206 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 356 365 328 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g003">Figure 3B</xref>
###xml 382 383 350 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 418 419 382 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 505 520 469 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g003">Figure 3C and D</xref>
###xml 693 694 649 650 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 90 96 <span type="species:ncbi:9986">rabbit</span>
###xml 206 212 <span type="species:ncbi:9986">rabbit</span>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
###xml 406 412 <span type="species:ncbi:9986">rabbit</span>
###xml 453 456 <span type="species:ncbi:10116">rat</span>
We next raised a peptide antibody against the second extracellular loop of the alpha1-AR (rabbit alpha1-AB) and purified the antibody on the same peptide-containing affinity matrix. In SPR experiments, the rabbit alpha1-AB produced regular association and dissociation kinetics reaching a signal of approximately2500 RU at a concentration of 80 microg/ml (Figure 3B). Purified alpha1-AAB from patients and rabbit alpha1-AB increased the beating rate of rat cardiomyocytes. This effect was dose-dependent (Figure 3C and D). The maximal response was obtained at an antibody dilution of 1:200 (0.5 and 0.6 microg/ml medium, respectively). The positive chronotropic effect was blocked by the alpha1-AR antagonist prazosin (1 microM).
###end p 25
###begin p 26
###xml 52 53 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 228 229 220 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 286 287 274 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 324 325 308 309 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 497 505 481 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLA2-IIA</italic>
###xml 510 518 494 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cacna1c,</italic>
###xml 531 538 515 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003742-t002">Table 2</xref>
###xml 597 598 577 578 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 264 272 <span type="species:ncbi:9606">patients</span>
###xml 274 280 <span type="species:ncbi:9986">rabbit</span>
###xml 292 297 <span type="species:ncbi:9606">human</span>
To elucidate the molecular pathways induced by alpha1-AAB, we performed gene expression studies. We used Affymetrix microarrays for quantification of mRNA expression in cardiomyocytes and VSMC after treatment with purified alpha1-AAB isolated from three different patients, rabbit alpha1-AB, human control IgG, and the alpha1-AR agonist phenylephrine (PE) for 24 h. We identified two genes with increased expression in the Affymetrix array that we then verified by TaqMan RT-PCR. These genes were PLA2-IIA and Cacna1c, as shown in Table 2. The upregulation of both genes was inhibited by the alpha1-AR antagonist prazosin while no changes in gene expression were observed after the treatment with the control IgG.
###end p 26
###begin title 27
###xml 27 35 27 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLA2-IIA</italic>
###xml 40 47 40 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cacna1c</italic>
###xml 109 110 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 135 136 127 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 96 103 <span type="species:ncbi:9606">patient</span>
###xml 116 122 <span type="species:ncbi:9986">rabbit</span>
###xml 123 129 <span type="species:ncbi:9986">rabbit</span>
Differential expression of PLA2-IIA and Cacna1c in cardiomyocytes and VSMC after treatment with patient alpha1-AAB, rabbit rabbit alpha1-AB or PE (Fold changes in TaqMan analysis).
###end title 27
###begin p 28
###xml 30 31 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 66 67 58 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 86 88 78 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 98 107 90 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g004">Figure 4A</xref>
###xml 170 172 162 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 241 242 229 230 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 453 454 437 438 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 471 472 451 452 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 520 522 500 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 599 601 579 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 651 652 627 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 703 704 675 676 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 721 730 693 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g004">Figure 4B</xref>
###xml 749 750 717 718 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 789 791 757 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 959 968 927 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g004">Figure 4C</xref>
###xml 999 1000 963 964 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1064 1066 1028 1030 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 54 60 <span type="species:ncbi:9986">rabbit</span>
###xml 228 235 <span type="species:ncbi:9606">patient</span>
###xml 691 697 <span type="species:ncbi:9986">rabbit</span>
###xml 737 743 <span type="species:ncbi:9986">rabbit</span>
###xml 861 866 <span type="species:ncbi:9606">human</span>
###xml 1014 1021 <span type="species:ncbi:9606">patient</span>
We tested whether or not alpha1-AAB from patients and rabbit alpha1-AB could elicit Ca2+ signals. Figure 4A shows the reaction of neonatal cardiomyocytes intracellular Ca2+ transients in response to the addition of the purified patient alpha1-AAB. There was a fast increase in the 340 nm/380 nm ratio, which peaked at less than 60 seconds and declined within 2 minutes to a plateau value slightly above the control level before the addition of the alpha1-AAB. Thus, alpha1-AAB potently induced a rise in intracellular Ca2+ in the targeted neonatal cardiomyocytes. To elucidate whether or not this Ca2+ response could be common to an autoantibody-alpha1-AR loop 2-type interaction, we used a rabbit alpha1-AB. As shown in Figure 4B, this rabbit alpha1-AB also generated an acute positive Ca2+ response in the cardiomyocytes with a similar time course as did the human antibody preparation. These responses were not elicited by a control IgG. As illustrated in Figure 4C, an IgG prepared from an alpha1-AAB negative patient was not able to raise the intracellular Ca2+.
###end p 28
###begin title 29
###xml 54 56 54 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 132 133 128 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 154 155 146 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 80 83 <span type="species:ncbi:10116">rat</span>
###xml 119 126 <span type="species:ncbi:9606">patient</span>
###xml 142 148 <span type="species:ncbi:9986">rabbit</span>
Representative traces of responses in intracellular Ca2+ of cultivated neonatal rat cardiomyocytes exposed to isolated patient alpha1-AAB and rabbit alpha1-AB are shown.
###end title 29
###begin p 30
###xml 9 10 5 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 94 96 90 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 125 126 117 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 147 149 139 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 231 233 223 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 303 305 295 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 44 51 <span type="species:ncbi:9606">patient</span>
###xml 113 119 <span type="species:ncbi:9986">rabbit</span>
###xml 164 169 <span type="species:ncbi:9606">human</span>
(A) alpha1-AAB isolated from the serum of a patient with refractory hypertension elicited a Ca2+ signal. (B) The rabbit alpha1-AB gave a similar Ca2+ signal. (C) A human control IgG preparation was unable to affect intracellular Ca2+. Cardiomyocytes were electrically stimulated at 1 Hz, and the peak Ca2+ was monitored.
###end p 30
###begin p 31
###xml 82 90 82 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g005">Figure 5</xref>
###xml 181 182 177 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 226 235 222 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g005">Figure 5A</xref>
###xml 257 258 249 250 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 302 303 290 291 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 430 431 414 415 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 452 453 432 433 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 548 557 528 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g005">Figure 5B</xref>
###xml 169 175 <span type="species:ncbi:9986">rabbit</span>
###xml 272 280 <span type="species:ncbi:9606">patients</span>
###xml 290 296 <span type="species:ncbi:9986">rabbit</span>
###xml 417 424 <span type="species:ncbi:9606">Patient</span>
###xml 440 446 <span type="species:ncbi:9986">rabbit</span>
###xml 515 520 <span type="species:ncbi:9606">human</span>
###xml 525 532 <span type="species:ncbi:9986">rabbits</span>
These results prompted myographic experiments in mesenteric arteries displayed in Figure 5. Treatment with KCl documented brisk viability of the preparation. PE and the rabbit alpha1-AB both were able to constrict the vessel (Figure 5A). The effect of alpha1-AAB from two patients and from rabbit alpha1-AB was compared to half-maximal and maximal effective PE dosages, producing 50% and 100% of vessel constriction. Patient alpha1-AAB and rabbit alpha1-AB showed marked vasoconstriction activity. Control IgG from human and rabbits had no effect (Figure 5B).
###end p 31
###begin title 32
###xml 35 36 31 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 57 58 49 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 22 29 <span type="species:ncbi:9606">patient</span>
###xml 45 51 <span type="species:ncbi:9986">rabbit</span>
Contractile effect of patient alpha1-AAB and rabbit alpha1-AB in mesenteric arteries is given.
###end title 32
###begin p 33
###xml 154 155 146 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 282 283 266 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 361 362 337 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 647 648 611 612 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 142 148 <span type="species:ncbi:9986">rabbit</span>
###xml 271 276 <span type="species:ncbi:9606">human</span>
###xml 306 314 <span type="species:ncbi:9606">patients</span>
###xml 349 355 <span type="species:ncbi:9986">rabbit</span>
###xml 526 533 <span type="species:ncbi:9606">patient</span>
###xml 540 547 <span type="species:ncbi:9606">patient</span>
###xml 555 560 <span type="species:ncbi:9606">human</span>
###xml 635 641 <span type="species:ncbi:9986">rabbit</span>
###xml 728 733 <span type="species:ncbi:9606">human</span>
###xml 746 752 <span type="species:ncbi:9986">rabbit</span>
A brisk KCl response is documented. (A) Representative experiment showing the contractile response to phenylephrine (PE, 10 nM-10 microM) and rabbit alpha1-AB (50 microg in 5 ml PBS buffer). The PE and antibody responses were similar in kind. (B) Contractile response of human alpha1-AAB isolated from two patients (5 microg in 5 ml PBS buffer) and rabbit alpha1-AB (50 microg in 5 ml PBS buffer) are compared to the PE response (300 nM and 10 microM, respectively) is shown. Contractions are expressed as % KCl response from patient 1 and patient 2. The human antibody responses were less than the low and high-dose PE responses. The rabbit alpha1-AB responses approached the PE responses. Two columns on the right are control human and control rabbit IgG showing no response.
###end p 33
###begin p 34
###xml 127 128 119 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 184 187 176 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Piascik1">[6]</xref>
###xml 201 209 193 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g006">Figure 6</xref>
###xml 230 231 218 219 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 252 253 236 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 541 547 513 515 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#913;</sub>
###xml 561 567 525 527 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#913;</sub>
###xml 582 583 538 539 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 705 706 653 654 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 712 721 660 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g007">Figure 7A</xref>
###xml 240 246 <span type="species:ncbi:9986">rabbit</span>
###xml 472 487 <span type="species:ncbi:10029">Chinese hamster</span>
###xml 530 535 <span type="species:ncbi:9606">human</span>
We then examined signal transduction. We concentrated on PKC-alpha and ERK 1/2 as both have been shown to be important in alpha1-AR-stimulated hypertension-induced target organ damage [6]. As shown in Figure 6, we found that alpha1-AAB and rabbit alpha1-AB exposure to cardiomyocytes or VSMC resulted in PKC-alpha activation, as did the positive PE control. These effects were blocked completely by the specific PKC-alpha blocker, Go 6976. Additionally, the incubation of Chinese hamster ovary (CHO) cells stably transfected with human alpha1Alpha-AR (CHO/alpha1Alpha-AR) with alpha1-AAB resulted in PKC-alpha activation, which was blocked by the peptide P2, corresponding to the binding site of the alpha1-AAB (Figure 7A).
###end p 34
###begin title 35
###xml 141 142 133 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 178 179 166 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
###xml 166 172 <span type="species:ncbi:9986">rabbit</span>
Protein kinase C alpha (PKC-alpha) activation in cardiomyocytes and vascular smooth muscle cells (VSMC) after 2 min incubation with PE, alpha1-AAB from patients, and rabbit alpha1-AB is demonstrated.
###end title 35
###begin p 36
###xml 75 76 71 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 98 99 90 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 62 69 <span type="species:ncbi:9606">patient</span>
###xml 86 92 <span type="species:ncbi:9986">rabbit</span>
Horizontal rows show regimens, namely, untreated control, PE, patient alpha1-AAB, and rabbit alpha1-AB. Vertical columns show cardiomyocyte and VSMC responses. Yellow shows PKC-alpha activation; red is more intense activation. Go 6976 is a PKC-alpha inhibitor, which blocked all responses.
###end p 36
###begin p 37
###xml 114 120 110 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#913;</sub>
###xml 158 159 146 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 276 285 264 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g007">Figure 7B</xref>
###xml 343 344 327 328 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 468 476 452 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g008">Figure 8</xref>
###xml 484 485 464 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 598 599 574 575 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 672 681 648 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g008">Figure 8A</xref>
###xml 730 736 702 704 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#913;</sub>
###xml 802 811 770 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003742-g008">Figure 8B</xref>
###xml 147 152 <span type="species:ncbi:9606">human</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
###xml 501 509 <span type="species:ncbi:9606">patients</span>
###xml 586 592 <span type="species:ncbi:9986">rabbit</span>
###xml 836 844 <span type="species:ncbi:9606">patients</span>
We then studied ERK 1/2 phosphorylation and the upstream phosphatidylinositol 3 (PI3)-kinase activity in CHO/alpha1Alpha-AR cells. Incubation with human alpha1-AAB resulted in ERK 1/2 phosphorylation. The PI3-kinase inhibitor, LY294002, inhibited the ERK 1/2 phosphorylation (Figure 7B). Additional hypertensive patients, who were either alpha1-AAB positive or negative in cardiomyocyte contraction assay, were characterized by ERK 1/2 activation with immunoblotting (Figure 8). alpha1-AAB from three patients induce a transient ERK 1/2 phosphorylation similar to that evoked by PE and rabbit alpha1-AB in neonatal cardiomyocytes. Phosphorylation was blocked by prazosin (Figure 8A). A similar activation was obtained in CHO/alpha1Alpha-AR cells. The activation was specifically blocked by peptide P2 (Figure 8B). Fractions eluted from patients, who were negative in the cardiomyocyte contraction assay, failed to activate ERK 1/2.
###end p 37
###begin title 38
###xml 81 87 73 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#913;</sub>
###xml 101 107 85 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#913;</sub>
###xml 120 121 96 97 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 70 75 <span type="species:ncbi:9606">human</span>
PKC-alpha and ERK 1/2 activation in CHO cells stably transfected with human alpha1Alpha-AR (CHO/alpha1Alpha-AR) by alpha1-AAB is demonstrated.
###end title 38
###begin p 39
###xml 27 33 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#913;</sub>
###xml 53 54 41 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 224 225 204 205 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
(A) Incubation of CHO/alpha1Alpha-AR cells with alpha1-AAB for 2 min resulted in a PKC-alpha activation, which was blocked by the peptide P2, but not by the peptide P5. (B) ERK 1/2 phosphorylation after incubation with alpha1-AAB for 5 min is shown. Inhibition of the upstream phosphatidylinositol 3 (PI3)-kinase activity by the inhibitor LY294002 strongly reduced ERK 1/2 phosphorylation. Yellow shows PKC-alpha and ERK 1/2 activation, respectively; red is more intense activation.
###end p 39
###begin title 40
###xml 61 62 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 96 97 88 89 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 84 90 <span type="species:ncbi:9986">rabbit</span>
Activation of ERK 1/2 in response to treatment with PE, alpha1-AAB from patients or rabbit alpha1-AB is shown.
###end title 40
###begin p 41
###xml 87 88 75 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 108 109 92 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 311 312 291 292 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 334 335 310 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 384 390 356 358 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#913;</sub>
###xml 433 434 397 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 516 517 476 477 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 614 615 570 571 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 664 665 616 617 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 783 784 731 732 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 96 102 <span type="species:ncbi:9986">rabbit</span>
###xml 298 305 <span type="species:ncbi:9606">patient</span>
###xml 322 328 <span type="species:ncbi:9986">rabbit</span>
###xml 420 427 <span type="species:ncbi:9606">patient</span>
###xml 490 498 <span type="species:ncbi:9606">Patients</span>
###xml 572 579 <span type="species:ncbi:9606">Patient</span>
###xml 629 637 <span type="species:ncbi:9606">patients</span>
###xml 639 647 <span type="species:ncbi:9606">Patients</span>
###xml 798 806 <span type="species:ncbi:9606">patients</span>
(A) Cardiomyocytes were treated for 5 and 15 min with 10 microM PE, 2.5 microg/ml alpha1-AAB or rabbit alpha1-AB, respectively. Equivalent amounts of protein were analyzed by Western blotting with anti-pERK 1/2 antibody (44/42 kD) and the amount of ERK was analyzed with anti-ERK 1/2 antibody. PE, patient alpha1-AAB, and rabbit alpha1-AB caused ERK 1/2 phosphorylation. (B) CHO/alpha1Alpha-AR cells were incubated with patient alpha1-AAB for 5 min. Lane 1 and 2 represent untreated cells. Patients 1, 4-8 were alpha1-AAB-positive in the cardiomyocyte contraction assay. "Patient" 9 represents a pool of five alpha1-AAB positive patients. Patients 10-12 were alpha1-AAB negative in the cardiomyocyte contraction assay. Their serum samples were processed identically to those of alpha1-AAB-positive patients. ERK 1/2 phosphorylation was inhibited by peptide P2, but not by peptide P5. Eukaryotic initiation factor 4E (elF4E, 25 kD) antibody was used as translational control, the amount of ERK was analyzed with anti-ERK 1/2 antibody.
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 60 61 56 57 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 85 86 77 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 217 219 209 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 436 437 424 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 458 459 442 443 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 502 510 486 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLA2-IIA</italic>
###xml 515 522 499 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cacna1c</italic>
###xml 598 599 578 579 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 654 655 630 631 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 423 430 <span type="species:ncbi:9606">patient</span>
###xml 446 452 <span type="species:ncbi:9986">rabbit</span>
###xml 669 677 <span type="species:ncbi:9606">patients</span>
The important findings in this study are that isolated alpha1-AAB und generated alpha1-AB show similar binding characteristics by surface plasmon resonance sensorgram and functional testing. The antibodies induce a Ca2+ dependent signal transduction cascade in VSMC and cardiomyocytes that are both important to the pathophysiology of hypertension and cardiac remodeling. By gene array studies, we showed that the isolated patient alpha1-AAB and rabbit alpha1-AB both upregulate two gene types, namely PLA2-IIA and Cacna1c. In a proof-of-concept, non-controlled trial, we show that removal of alpha1-AAB by immunoadsorption lowers blood pressure in alpha1-AAB positive patients with intractable primary hypertension.
###end p 43
###begin p 44
###xml 102 106 102 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Luft1">[17]</xref>
###xml 439 440 435 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 554 558 547 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Luft1">[17]</xref>
The entire idea of "agonistic" autoantibodies contributing to cardiovascular disease is controversial [17]. Antibodies directed at receptors can block or stimulate their targets. Hallmark example of the latter action is Graves' disease where antibodies directed at the thyroid stimulating hormone receptor exert an agonistic action. Recently, compelling evidence has been presented regarding agonistic antibodies directed against the alpha1-AR, the beta-ARs, the Ang II AT1-R, and the platelet-derived growth factor-alpha receptor, as reviewed elsewhere [17]. The antibodies could play a pathogenic role in various cardiovascular diseases, including hypertension, cardiomyopathy, preeclampsia, acute humoral rejection, and connective tissue disease.
###end p 44
###begin p 45
###xml 33 34 29 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 72 76 68 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Luther1">[15]</xref>
###xml 123 124 115 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 212 213 200 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 309 310 293 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 390 391 370 371 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 968 969 944 945 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1104 1105 1076 1077 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1148 1149 1116 1117 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1328 1329 1293 1294 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1514 1518 1479 1483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Boivin1">[18]</xref>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
###xml 1218 1226 <span type="species:ncbi:9606">patients</span>
Earlier, we speculated that alpha1-AAB could contribute to hypertension [15]. Our goal here was to give the notion of alpha1-AAB a more robust scientific basis. Thus, we verified our candidate by generating alpha1-AB by immunization. Concomitantly, we subjected patients from our collective who harbored alpha1-AAB to immunoadsorption. We found in our uncontrolled trial that lowering alpha1-AAB titers was associated with a lower blood pressure. We did not perform a randomized double blind, crossover trial. Nonetheless, our study meets class I (safety) criteria and suggests that a future class II (efficacy) trial might be warranted. We cannot exclude the possibility that short-term effects of the immunoadsorption, such as circulating blood volume changes during apheresis or other confounders contributed to the reduction in blood pressure. Since the reduction in blood pressure persisted for the observation period of 180 days, we believe that removal of alpha1-AAB by apheresis was the main cause for the blood pressure reduction. Within the five days immunoadsorption period, the level of alpha1-AAB decreased gradually. Thereafter, alpha1-AAB could not be detected after successful immuoadsorption in these patients for the entire observation period of 180 days. A similar state-of-affairs has been described for beta1-AAB in dilated cardiomyopathy after immunoadsorption. These data suggest that immunomodulation by removal or neutralization of the AAB might represent a potential therapeutic strategy [18].
###end p 45
###begin p 46
###xml 30 31 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 49 50 41 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 368 369 356 357 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 426 427 410 411 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 766 774 750 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLA2-IIA</italic>
###xml 779 786 763 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cacna1c</italic>
###xml 1236 1240 1220 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Kugiyama1">[19]</xref>
###xml 1242 1246 1226 1230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Nevalainen1">[20]</xref>
###xml 1248 1252 1232 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Porela1">[21]</xref>
###xml 1347 1351 1331 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Masuda1">[22]</xref>
###xml 1443 1447 1427 1431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Levick1">[23]</xref>
###xml 100 107 <span type="species:ncbi:9986">rabbits</span>
###xml 276 282 <span type="species:ncbi:9986">rabbit</span>
###xml 1438 1442 <span type="species:ncbi:10116">rats</span>
We isolated the detected alpha1-AAB and the alpha1-AB that we generated against the same epitope in rabbits, using the same affinity purification protocol. Since we used the same peptide sequence for epitope mapping in the cardiomyocyte contraction assay, immunization in the rabbit, and isolation in the affinity column, we are confident that we isolated solely alpha1-AB. Before using this material to learn more about alpha1-AR signaling in VSMC and cardiomyocytes, we confirmed binding specificity by functional (cardiac contraction assay and ERK 1/2 phosphorylation) and biochemical (surface plasmon resonance measurement) verification methods. We then performed an Affymetrix gene expression study. We followed up on the results to pursue two candidate genes, PLA2-IIA and Cacna1c that were upregulated in the display, as verified by RT-PCR. Both genes contribute to signaling pathways in hypertension and atherosclerosis. Phospholipases A2 are acute-phase reactants and play an important role in digestion and metabolism of phospholipids, as well as in production of precursors for inflammatory reactions. Plasma PLA2-IIA levels are increased in systemic inflammation, including, rheumatoid arthritis and cardiovascular diseases [19], [20], [21]. In infarcted hearts, expression of PLA2-IIA was markedly increased in damaged cardiomyocytes [22]. Inhibition of PLA2-IIA also prevented cardiac fibrosis in spontaneously hypertensive rats [23].
###end p 46
###begin p 47
###xml 65 66 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 105 106 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 135 137 127 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 221 223 213 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 295 297 287 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 425 427 417 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 468 470 460 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 559 560 547 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 597 599 585 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 663 667 651 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-OUchi1">[24]</xref>
###xml 710 711 694 695 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 779 781 763 765 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 790 794 774 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Bkaily1">[25]</xref>
###xml 796 800 780 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Thway1">[26]</xref>
###xml 835 837 819 821 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 904 906 888 890 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 930 932 914 916 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 974 976 958 960 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1003 1005 987 989 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1058 1060 1042 1044 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1081 1082 1065 1066 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1085 1087 1069 1071 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 93 99 <span type="species:ncbi:9986">rabbit</span>
###xml 638 641 <span type="species:ncbi:10116">rat</span>
###xml 682 688 <span type="species:ncbi:9986">rabbit</span>
Another important finding accrued is the fact that both the alpha1-AAB from patients and the rabbit alpha1-AB affected intracellular Ca2+ at two different levels, namely the acute, short-term elevation of intracellular Ca2+, and the increased transcript expression of the voltage-gated L-type Ca2+ channel pore subunit. Acute administration of the purified antibodies to neonatal cardiomyocytes produced a typically shaped Ca2+ transient. The onset of the cytosolic Ca2+ response occurred within few seconds reaching its maximum at less than one minute. alpha1-AR stimulation potentiates L-type Ca2+ current through CaMK II activation in rat ventricular myocytes [24]. Furthermore, rabbit antibody to the alpha1AR and autoantibodies against the AT1-receptor could activate the Ca2+ current [25], [26]. The peak response of cytosolic Ca2+ to the antibodies apparently comprises a temporary imbalance of Ca2+ entry through L-type Ca2+ channel and the sarcoplasmic reticulum Ca2+ release on one hand and Ca2+ sequestration into the sarcoplasmic reticulum and Ca2+ extrusion via the Na+/Ca2+ exchanger on the other hand.
###end p 47
###begin p 48
###xml 23 25 23 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 94 95 90 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 123 124 115 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 145 146 133 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 212 214 200 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 240 247 224 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cacna1c</italic>
###xml 313 315 297 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 520 522 504 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 586 588 570 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 622 624 606 608 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 958 960 923 925 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 978 982 943 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Bodi1">[27]</xref>
###xml 1053 1054 1010 1011 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1123 1125 1080 1082 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1160 1162 1117 1119 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1261 1266 1218 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1328 1330 1285 1287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1401 1402 1354 1355 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1418 1422 1371 1375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Pignier1">[28]</xref>
###xml 1442 1447 1395 1400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1518 1519 1467 1468 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1581 1585 1526 1530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Maki1">[29]</xref>
###xml 1698 1702 1639 1643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Haase1">[30]</xref>
###xml 110 117 <span type="species:ncbi:9606">patient</span>
###xml 133 139 <span type="species:ncbi:9986">rabbit</span>
###xml 1476 1479 <span type="species:ncbi:10116">rat</span>
###xml 1686 1691 <span type="species:ncbi:9606">human</span>
In addition to acute Ca2+ current stimulation, we found that long-term activation of the alpha1-AR pathway by patient alpha1-AAB and rabbit alpha1-AB increases transcript levels of the voltage-dependent L-type Ca2+ channel alpha1C subunit (Cacna1c) in neonatal cardiomyocytes and VSMC. Voltage-dependent L-type Ca2+ channels (L-VDCC) play a crucial role in the regulation of heart rhythm and contractile performance, as well as in smooth muscle tone. The channels open in response to membrane depolarization providing Ca2+ ingress into the cell. In the myocardium, this local rise in Ca2+ concentration triggers massive Ca2+ release from the sarcoplasmic reticulum stores inducing in turn contraction. L-VDCC expressed in cardiac and smooth muscle are multi-subunit proteins containing the alpha1C, alpha2/delta, and beta subunits. The alpha1C subunit forms the ion-selective pore, determines voltage sensitivity, and is a binding site for clinically used Ca2+ channel blockers [27]. Thus, upregulation of alpha1C subunit expression in response to alpha1-AR stimulation observed herein provides the route for an enhanced Ca2+ ingress which may contribute to Ca2+ imbalances and translate in cardiac dysfunction. Our results are consistent with those of Pignier et al. who reported on increased expression of functional L-type Ca2+ channels and hypertrophy in neonatal cardiomyocytes upon chronic alpha1-AR stimulation [28]. In contrast, Maki et al. described that in neonatal rat cardiomyocytes activation of the alpha1-AR pathway was accompanied by attenuated alpha1C mRNA levels [29]. A link between increased alpha1C protein levels and hypertrophy has also been demonstrated for the human heart [30].
###end p 48
###begin p 49
###xml 73 75 73 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Muth1">[31]</xref>
###xml 215 217 211 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 372 374 368 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 468 472 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Muth2">[32]</xref>
###xml 586 587 574 575 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 707 710 695 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Piascik1">[6]</xref>
###xml 712 716 700 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Iijima1">[33]</xref>
###xml 815 816 795 796 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 834 835 810 811 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 873 874 845 846 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 888 889 856 857 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 987 988 947 948 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1013 1014 969 970 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 804 809 <span type="species:ncbi:9606">human</span>
###xml 822 828 <span type="species:ncbi:9986">rabbit</span>
###xml 976 981 <span type="species:ncbi:9606">human</span>
###xml 1001 1007 <span type="species:ncbi:9986">rabbit</span>
A transgenic mouse with cardiac specific over-expression of solely the Ca2+ channel pore subunit has been studied intensively [31]. When alpha1C protein levels were increased by about 3-fold, a slightly increased Ca2+ inward current (30-40%) was observed, and the mice developed hypertrophy and severe cardiomyopathy as a function of age. The small sustained ingress of Ca2+ through the channel is capable of elevating PKC-alpha before the development of hypertrophy. [32] Activation of PKC in adult cardiomyocytes regulates ERK 1/2 through the c-RAF/MEK/ERK signaling pathway and alpha1-AR-stimulated hypertrophy in cardiomyocytes is mediated via activation of the Ras-Raf-MEK1/2-ERK 1/2 signaling pathway [6], [33]. As a consequence, we investigated the regulation of PKC-alpha and ERK 1/2 activity by human alpha1-AAB, rabbit alpha1-AB, or PE. We demonstrated that alpha1-AAB and alpha1-AB induced PKC-alpha stimulation and ERK 1/2 phosphorylation. Finally, we showed that human alpha1-AAB and the rabbit alpha1-AB evoke vasoconstriction in a vascular bed.
###end p 49
###begin p 50
###xml 82 83 78 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 218 219 210 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 350 352 342 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 403 404 391 392 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 578 579 562 563 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 123 128 <span type="species:ncbi:9606">human</span>
###xml 229 232 <span type="species:ncbi:9606">man</span>
###xml 237 244 <span type="species:ncbi:9986">rabbits</span>
Taken together, we present data from a limited, uncontrolled, human trail of alpha1-AAB removal from severely hypertensive human subjects. This trial presents a hypothesis-generating result. We show that isolated alpha1-AAB from man and rabbits cause gene upregulation important to hypertension-relevant pathways and then document the induction of Ca2+-dependent pathways. We provide evidence that alpha1-AAB are of potential pathophysiological relevance and could represent a factor contributing to the development of refractory hypertension. Removal or neutralization of alpha1-AAB might represent a possible therapeutic option. Accordingly, we suggest that the entire gamut of autoimmunity in chronic cardiovascular disease warrants further critical inspection.
###end p 50
###begin title 51
Materials and Methods
###end title 51
###begin title 52
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 52
###begin p 53
###xml 531 532 527 528 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 671 675 667 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Wallukat2">[34]</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 297 305 <span type="species:ncbi:9606">patients</span>
###xml 488 500 <span type="species:ncbi:9606">participants</span>
###xml 507 515 <span type="species:ncbi:9606">patients</span>
Patients requiring three or more medication classes to achieve goal control blood pressure values were recruited from the Franz-Volhard Clinic outpatient department. All had been studied intensively and secondary causes of hypertension had been ruled out. Home and clinic blood pressures in these patients were determined with an automated oscillometric device under standardized conditions. The internal review board approved the study and written informed consent was obtained from all participants. Five patients harboring alpha1-AAB were asked to undergo five immunoadsorption treatments with an especially prepared column according to procedures described elsewhere [34].
###end p 53
###begin title 54
###xml 5 6 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
alpha1-AAB detection
###end title 54
###begin p 55
###xml 77 80 77 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Wallukat1">[4]</xref>
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Luther1">[15]</xref>
###xml 418 424 414 416 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#913;</sub>
###xml 827 828 807 808 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 995 996 971 972 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 173 176 <span type="species:ncbi:10116">rat</span>
###xml 407 412 <span type="species:ncbi:9606">human</span>
###xml 621 624 <span type="species:ncbi:10116">rat</span>
We isolated immunoglobulin fractions from serum samples as described earlier [4], [15]. For detection of autoantibodies, the immunoglobulin fractions were added to neonatal rat cardiomyocytes at a dilution of 1:20. For the neutralization experiments, synthetic peptides corresponding to the sequence of the first extracellular loop (YWAFGRVFCNIWA), and the second extracellular loop (PAPEDETICQINEE) of the human alpha1Alpha-AR were each added in excess (0.05 to 0.1 microg) to the immunoglobulin fraction. The mixtures were shaken and placed in a refrigerator for 1 h. The 100 microl samples were then added to neonatal rat heart muscle cells cultured in 2 ml of medium to a final dilution of 1:40. The beating rate was counted for 15 sec, 5 and 60 min after the addition of the peptide/immunoglobulin mixture. We tested alpha1-AAB activity in a neonatal cardiomyocyte assay without and with peptide inhibition. Pulsation rate was exhibited 1 h or 24 h, respectively after incubation with alpha1-AAB and compared with the spontaneous basal pulsation rate. Eight synchronously contracting cell clusters per flask were counted for 15 sec on a heat table stage.
###end p 55
###begin title 56
###xml 5 6 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 24 30 <span type="species:ncbi:9986">rabbit</span>
alpha1-AB generation in rabbit and antibody purification
###end title 56
###begin p 57
###xml 144 145 140 141 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 273 274 265 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 13 20 <span type="species:ncbi:9986">rabbits</span>
###xml 133 138 <span type="species:ncbi:9606">human</span>
We immunized rabbits against a peptide corresponding to the amino acid sequence of the second extracellular loop of the isoform A of human alpha1-AR (PAPEDETICQINEE) by BioGenes GmbH (Berlin, Germany). The corresponding peptide of the second extracellular loop of the alpha1-AR was covalently bound to epsilon-aminocapryl agarose (Sigma-Aldrich, Munich, Germany) to yield epitope-specific affinity beads. For coupling the agarose gel matrix (approximately1 ml of packed gel) was activated by glutaraldehyde (1% solution, freshly prepared) for 20 min at room temperature on a rotating wheel. The activated gel was extensively washed with PBS and allowed to react with the peptide solution for 3 h at room temperature or overnight at 4degreesC on a rotating wheel. The coupling reaction was terminated by incubation with 200 mM Tris/Glycine buffer pH 7.2. The affinity beads were poured into a column (Bio-Rad, Munich, Germany) and stored with 0.02% sodium acid in buffer A consisting of 50 mM Tris/HCl, 0.5 M NaCl, pH 7.4, at 4degreesC.
###end p 57
###begin p 58
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 157 164 <span type="species:ncbi:9986">rabbits</span>
The affinity beads were washed with buffer A to remove the sodium acid. Serum samples (5-15 ml) from patients with refractory hypertension or from immunized rabbits were incubated with the affinity beads overnight at 4degreesC on a rotating wheel. The beads were allowed to settle and the sera were removed and stored for a second round of affinity purification at a given matrix. The beads were washed with buffer A until baseline levels of protein are detected at 280 nm. The antibodies were eluted at room temperature in 1 ml fractions with 50 mM Tris/Glycine, 0.5 M NaCl, pH 2.5. Antibody fractions were immediately neutralized with 0.5 ml of 0.5 M Tris/HCl, 0.5 M NaCl, pH 7.4. The antibody concentration was calculated by measurement the absorption at 280 nm.
###end p 58
###begin title 59
Surface plasmon resonance measurements
###end title 59
###begin p 60
###xml 200 202 190 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1A</sub>
###xml 948 951 934 937 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">off</sub>
###xml 948 951 934 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>off</sub></italic>
###xml 954 956 940 942 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">on</sub>
###xml 954 956 940 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>on</sub></italic>
###xml 967 970 953 956 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">off</sub>
###xml 967 970 953 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>off</sub></italic>
###xml 976 978 962 964 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">on</sub>
###xml 976 978 962 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>on</sub></italic>
###xml 349 356 <span type="species:ncbi:9606">patient</span>
Binding experiments were performed in a BIAcore 2000 Instrument (Uppsala Sweden) at 25degreesC. N-terminally biotinylated peptides corresponding to the first and second extracellular loop of the alpha1A-AR were immobilized at binding levels of 100 relative units (RU) each on parallel lanes of a SA-biosensor chip. Affinity-purified antibodies from patient blood samples were injected in the flow cells at a rate of 20 microl/min in HBSE running buffer consisting of 10 mM HEPES, pH 7.4, 150 mM NaCl, and 3 mM EDTA. The binding was regenerated between binding measurements using 5 mM Tris/Glycine, 50 mM NaCl, pH 2.5, with no decrease in extent measurements over the duration of an experiment. Data were analyzed using the using the BIAevaluation 3.2 RC 1 program. The analysis software corrects for baseline drift during measurements. The curves were fitted to a single-site interaction model. Kd values were calculated by using the formula Kd = koff /kon in which koff and kon is the rate constant of dissociation and association kinetics, respectively.
###end p 60
###begin title 61
Cell culture and autoantibody incubation
###end title 61
###begin p 62
###xml 109 113 109 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Wallukat3">[35]</xref>
###xml 379 383 369 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Shagdarsuren1">[36]</xref>
###xml 435 441 421 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#913;</sub>
###xml 455 461 433 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#913;</sub>
###xml 613 617 587 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Keffel1">[37]</xref>
###xml 784 785 750 751 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 850 851 808 809 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 897 898 847 848 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1144 1150 1086 1088 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#913;</sub>
###xml 1258 1259 1192 1193 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1279 1280 1209 1210 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1478 1479 1392 1393 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1562 1568 1472 1474 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#913;</sub>
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
###xml 73 84 <span type="species:ncbi:10116">Wistar rats</span>
###xml 235 239 <span type="species:ncbi:9913">calf</span>
###xml 350 354 <span type="species:ncbi:10116">rats</span>
###xml 424 429 <span type="species:ncbi:9606">human</span>
###xml 706 711 <span type="species:ncbi:9606">human</span>
###xml 805 813 <span type="species:ncbi:9606">patients</span>
###xml 838 844 <span type="species:ncbi:9986">rabbit</span>
###xml 1247 1252 <span type="species:ncbi:9606">human</span>
###xml 1267 1273 <span type="species:ncbi:9986">rabbit</span>
Rat neonatal cardiomyocytes were prepared from ventricles of 1-2 day-old Wistar rats using a modified method [35]. The cells were cultured as monolayers for 4 days at 37degreesC in SM 20-1 medium supplemented with 10% heat-inactivated calf serum, 2 microM fluorodeoxyuridine and penicillin/streptomycin. Aortic VSMC were isolated from Sprague Dawley rats as described previously [36]. CHO cells were stably transfected with human alpha1Alpha-AR (CHO/alpha1Alpha-AR) using a pSW104 vector and were cultured in F12 HAM medium supplemented with glutamine, 10% FCS and 1% penicillin/streptomycin as described earlier [37]. For gene expression analysis cardiomyocytes and VSMC, respectively were incubated with human control IgG endobulin (5 microg/ml medium, Baxter, Wien, Austria), alpha1-AAB from different patients (2.5 microg/ml medium), rabbit alpha1-AB (2.5 microg/ml medium), and with the alpha1-AR agonist PE (10 microM, Sigma-Aldrich) for 24 h in DMEM medium containing 1% serum. Experiments were repeated with three different cardiomyocytes and VSMC preparations. For investigation of protein phosphorylation, cardiomyocytes and CHO/alpha1Alpha-AR cells were maintained in serum-free media for 24 h or 4 h, respectively and treated with PE, human alpha1-AAB or rabbit alpha1-AB for 5 and 15 min, respectively. For inhibition experiments, prazosin (1 microM, Sigma-Aldrich) was added. Five microg of the peptides P2 (APEDET) or P5 (GYVLFS) were given to 2.5 microg of alpha1-AAB 1 h before cell treatment. For the inhibition of ERK 1/2 activation, CHO/alpha1Alpha-AR cells were pre-incubated with PI3-kinase inhibitor LY294002 for 10 min.
###end p 62
###begin title 63
Gene expression analysis
###end title 63
###begin p 64
###xml 80 81 76 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 99 100 91 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 832 836 820 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Irizarry1">[38]</xref>
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 87 93 <span type="species:ncbi:9986">rabbit</span>
###xml 485 488 <span type="species:ncbi:10116">Rat</span>
We extracted total RNA from cardiomyocytes treated with human control IgG, alpha1-AAB, rabbit alpha1-AB or PE using the RNeasy Purification Kit (Qiagen GmbH, Hilden, Germany). RNA was treated by deoxyribonuclease I (Qiagen). Two microg RNA of cells were transcribed in cRNA with One-Cycle Target labeling and Control Reagents (Affymetrix, Santa Clara, CA, USA). Non-pooled microarray experiments were performed with cRNA prepared from independent cardiomyocyte cell preparations using Rat Genome 230 2.0 Arrays (31,099 probe sets, Affymetrix). After passing the quality control for each experiment a set of RMA normalized expression values have been produced. The log scale robust multi-array analysis (RMA) estimates are based upon a robust average of log2 (B (PM)), where B (PM) are background corrected perfect match intensities [38]. For statistical comparison of expression data student's t-test was used.
###end p 64
###begin title 65
Quantitative Real-Time Reverse Transcriptase PCR (TaqMan)
###end title 65
###begin p 66
###xml 198 200 194 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18</sub>
###xml 493 496 487 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B2M</italic>
###xml 544 549 538 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 768 772 762 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Livak1">[39]</xref>
###xml 805 812 799 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003742-t003">Table 3</xref>
cDNA was synthesized from 2 microg of total RNA isolated from cardiomyocytes and VSMC, respectively using PowerScript Reverse Transcriptase (BD Bioscience Clontech, Palo Alto, USA) and an Oligo (dT)18 primer. Real-time PCR experiments were done using the Mx3000P(R) real-time PCR system (Stratagene Europe, Amsterdam, NL) and the Brillant QPCR master mix (Stratagene Europe). Real-time PCR was performed with non-pooled samples from cardiomyocytes and VSMC respectively. Beta-2-microglobulin (B2M) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as endogenous references to normalize expression of a target gene. For every sample three independent runs in triplicates and the relative changes in gene expression were quantified by comparative Ct method [39]. Primer sequences are listed in Table 3.
###end p 66
###begin title 67
Primer and probe sequences used for TaqMan RT-PCR.
###end title 67
###begin p 68
Used annealing temperature was 58degreesC.
###end p 68
###begin title 69
Immunocytochemistry
###end title 69
###begin p 70
###xml 101 104 101 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Wallukat1">[4]</xref>
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Dechend1">[40]</xref>
###xml 602 607 <span type="species:ncbi:10090">mouse</span>
We described the techniques for confocal microscopy and immunocytochemistry as referenced previously [4], [40]. The cells were fixed with 4% paraformaldehyde and permeabilized with 80% methanol at -20degreesC. After incubation with 2% BSA in PBS for 60 minutes, the preparation was incubated for 1 hour at room temperature with the monoclonal anti-PKC-alpha antibody from UBI (clone M4) diluted in PBS with 1% BSA (1:80) or pERK 1/2 antibody (1:200, Cell Signaling Technology, Boston, MA, USA), respectively, washed twice with PBS, and then exposed to the secondary antibody (Alexa-488-conjugated anti-mouse IgG at 1:200, 1% BSA/PBS; Invitrogen, Life Technologies, Carlsbad, CA, USA) for 60 minutes. The preparation was mounted with AquaPolymount (Polyscience, Niles, IL, USA) under a glass coverslip on a Nikon-Diaphot microscope. An MRC 1024 confocal imaging system (Bio-Rad) with an argon/krypton laser was used. At least 25 to 40 cells from each of at least three experiments were examined under each experimental condition.
###end p 70
###begin title 71
Western blotting
###end title 71
###begin p 72
###xml 28 34 24 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#913;</sub>
###xml 749 753 <span type="species:ncbi:9925">goat</span>
###xml 759 765 <span type="species:ncbi:9986">rabbit</span>
Cardiomyocytes and CHO/alpha1Alpha-AR cells were scraped in lysis buffer [20 mM HEPES (pH7.9), 350 mM NaCl, 20% glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.1 mM EGTA, 1% NP40, complete protease inhibitor cocktail (Roche Diagnostic GmbH, Mannheim, Germany) and phosphatase inhibitor cocktail (Sigma-Aldrich)] and centrifuged at 10,000 rpm for 10 min. Protein concentrations were measured with Bradford method and equal amounts of proteins were analyzed by Western blotting. ERK phosphorylation was detected by pERK 1/2 antibody (1:1000, Cell Signaling Technology). As translational control an ERK antibody (1:1000, Cell Signaling Technology) and eukaryotic initiation factor 4E (elF4E) antibody (1:7000, Cell Signaling Technology) were used. HRP-conjugated goat anti-rabbit secondary antibody (1:5000, Jackson Immunoresearch Europe, Suffolk, UK) was used. Detection was performed with the ECLtrade mark-substrate (Lumigen, Southfield, MI, USA) according to the manufacturers instructions.
###end p 72
###begin title 73
###xml 27 29 27 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Measurement of cytosolic Ca2+ transients
###end title 73
###begin p 74
###xml 165 166 165 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 769 771 759 761 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1294 1296 1270 1272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1393 1395 1369 1371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Neonatal cardiomyocytes were plated onto Labtek four chamber slides (Nunc GmbH & Co, Wiesbaden, Germany) suited for fluorescence measurements at a densitiy of 0.2x106 cells per chamber. After cultivation for four days the medium was removed and cells were washed twice with 10 mM Hepes-buffered Hank's salt solution, pH 7.4 (HBSS). Cardiomyocytes were incubated on HBSS for 60 minutes at 37degreesC. Then the solution was replaced by 0.5 ml HBSS containing 2.5 microM final concentration of Fura 2-AM (Calbiochem AG, Luzern, Switzerland) and left for loading in the dark at room temperature. After 30 min the loading solution was aspirated, the cells washed and kept on 0.5 ml HBSS in the dark and at room for another 30 minutes before use. Measurements of cytosolic Ca2+ transients were performed on an IonOptix Fluorescence and Contractility System (Milton, MA, USA) equipped with a Leica microscope with a heatable stage. All measurements were carried out at 37degreesC. Cardiomyocytes were electrically stimulated at 1 Hz and the ratio of 340 nm/380 nm was recorded. After stabilization of the Fura signal the control trace was taken. Antibody preparations were applied in a constant volume of 100 microl of pre-warmed HBSS to give a final concentration of 2 microg/ml. For evaluation of Ca2+ changes peak values were derived from the trace recordings representing the maximum cytosolic Ca2+ achieved in the contracted cell.
###end p 74
###begin title 75
Contraction of mesenteric arteries
###end title 75
###begin p 76
###xml 189 193 189 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003742-Verlohren1">[41]</xref>
###xml 404 405 392 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 453 454 433 434 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 55 74 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
###xml 441 447 <span type="species:ncbi:9986">rabbit</span>
###xml 490 496 <span type="species:ncbi:9986">rabbit</span>
###xml 577 582 <span type="species:ncbi:9606">human</span>
Vessel rings from superior mesenteric arteries of male Sprague-Dawley rats (200 to 300 g, 6 to 8 weeks) were prepared and intracellular membrane potential was measured as earlier described [41]. In the first series of experiments, the rings were exposed to increasing doses of PE (10 nM-10 microM) and with acetylcholine (10 nM-10 microM) for relaxation. Following, vessel rings were incubated with alpha1-AAB (5 microg in 5 ml PBS buffer), rabbit alpha1-AB (50 microg in 5 ml PBS buffer), rabbit IgG (50 microg in 5 ml PBS buffer, Dunn Labortechnik GmBH, Asbach, Germany) and human control IgG endobulin (50 microg in 5 ml PBS buffer).
###end p 76
###begin title 77
Statistics
###end title 77
###begin p 78
We relied on student's t-tests (adjusted as necessary) for normally distributed data and performed analysis of variance (repeated measures were indicated). P<0.05 was accepted as significant. Data are expressed as mean+/-SD.
###end p 78
###begin p 79
###xml 325 327 321 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1A</sub>
###xml 314 319 <span type="species:ncbi:9606">human</span>
We thank Karin Karczewski and Petra Hempel for the cultivation of cardiomyocytes and Steffen Luther for the surface plasmon resonance measurements. We are indebted to Prof. Martin Michel, Dept. Pharmacology & Pharmacotherapy the University of Amsterdam, Netherlands for providing CHO cells stably transfected with human alpha1A-AR.
###end p 79
###begin title 80
References
###end title 80
###begin article-title 81
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 92 97 <span type="species:ncbi:9606">human</span>
Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets.
###end article-title 81
###begin article-title 82
The thyrotropin receptor in Graves' disease.
###end article-title 82
###begin article-title 83
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
###end article-title 83
###begin article-title 84
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor.
###end article-title 84
###begin article-title 85
Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy.
###end article-title 85
###begin article-title 86
Alpha1-adrenergic receptors: new insights and directions.
###end article-title 86
###begin article-title 87
Alpha 1-adrenergic receptor regulation: basic science and clinical implications.
###end article-title 87
###begin article-title 88
Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study.
###end article-title 88
###begin article-title 89
Effect of alpha1-adrenergic receptors in cardiac pathophysiology.
###end article-title 89
###begin article-title 90
An alpha1A-adrenergic-extracellular signal-regulated kinase survival signaling pathway in cardiac myocytes.
###end article-title 90
###begin article-title 91
###xml 126 131 <span type="species:ncbi:10090">mouse</span>
The alpha(1A/C)- and alpha(1B)-adrenergic receptors are required for physiological cardiac hypertrophy in the double-knockout mouse.
###end article-title 91
###begin article-title 92
Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload.
###end article-title 92
###begin article-title 93
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension.
###end article-title 93
###begin article-title 94
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension.
###end article-title 94
###begin article-title 95
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Alpha 1-adrenergic receptor antibodies in patients with primary hypertension.
###end article-title 95
###begin article-title 96
###xml 103 107 <span type="species:ncbi:10116">rats</span>
Cardiac remodeling after long-term stimulation by antibodies against the alpha1-adrenergic receptor in rats.
###end article-title 96
###begin article-title 97
Agonistic antibodies directed at cell-receptors and cardiovascular disease.
###end article-title 97
###begin article-title 98
Neutralizing cyclo-peptides added on beta-blocker therapy in beta1-receptor antibody-induced heart failure: reversal of cardiomyopathic phenotype and molecular markers of sympathetic activation.
###end article-title 98
###begin article-title 99
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Increase in plasma levels of secretory type II phospholipase A(2) in patients with coronary spastic angina.
###end article-title 99
###begin article-title 100
Roles of secretory phospholipases A(2) in inflammatory diseases and trauma.
###end article-title 100
###begin article-title 101
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction.
###end article-title 101
###begin article-title 102
###xml 80 85 <span type="species:ncbi:9606">human</span>
Diverse cellular localizations of secretory phospholipase A2 enzymes in several human tissues.
###end article-title 102
###begin article-title 103
###xml 114 118 <span type="species:ncbi:10116">rats</span>
Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats.
###end article-title 103
###begin article-title 104
###xml 127 130 <span type="species:ncbi:10116">rat</span>
alpha1-adrenoceptor stimulation potentiates L-type Ca2+ current through Ca2+/calmodulin-dependent PK II (CaMKII) activation in rat ventricular myocytes.
###end article-title 104
###begin article-title 105
Modulation of intracellular Ca2+ via L-type calcium channels in heart cells by the autoantibody directed against the second extracellular loop of the alpha1-adrenoceptors.
###end article-title 105
###begin article-title 106
###xml 29 37 <span type="species:ncbi:9606">patients</span>
Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation.
###end article-title 106
###begin article-title 107
The L-type calcium channel in the heart: the beat goes on.
###end article-title 107
###begin article-title 108
###xml 108 111 <span type="species:ncbi:10116">rat</span>
Alpha-adrenoceptor stimulation induces hypertrophy and increases L-type calcium current density in neonatal rat ventricular cardiomyocytes in culture.
###end article-title 108
###begin article-title 109
Regulation of calcium channel expression in neonatal myocytes by catecholamines.
###end article-title 109
###begin article-title 110
###xml 66 71 <span type="species:ncbi:9606">human</span>
Expression of calcium channel subunits in the normal and diseased human myocardium.
###end article-title 110
###begin article-title 111
###xml 106 121 <span type="species:ncbi:10090">transgenic mice</span>
Cardiac-specific overexpression of the alpha(1) subunit of the L-type voltage-dependent Ca(2+) channel in transgenic mice. Loss of isoproterenol-induced contraction.
###end article-title 111
###begin article-title 112
A Ca(2+)-dependent transgenic model of cardiac hypertrophy: A role for protein kinase Calpha.
###end article-title 112
###begin article-title 113
c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells.
###end article-title 113
###begin article-title 114
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy.
###end article-title 114
###begin article-title 115
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Anti-beta 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops.
###end article-title 115
###begin article-title 116
Complement activation in angiotensin II-induced organ damage.
###end article-title 116
###begin article-title 117
###xml 91 106 <span type="species:ncbi:10029">Chinese hamster</span>
alpha(1)-adrenoceptor subtypes differentially couple to growth promotion and inhibition in Chinese hamster ovary cells.
###end article-title 117
###begin article-title 118
Summaries of Affymetrix GeneChip probe level data.
###end article-title 118
###begin article-title 119
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
###end article-title 119
###begin article-title 120
###xml 52 60 <span type="species:ncbi:9606">patients</span>
AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase.
###end article-title 120
###begin article-title 121
###xml 55 58 <span type="species:ncbi:10116">rat</span>
Uterine vascular function in a transgenic preeclampsia rat model.
###end article-title 121
###begin p 122
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 122
###begin p 123
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The Deutsche Forschungsgemeinschaft supported RD, DNM, and FCL with separate grants-in-aid. Part of this work was supported by the ProFIT initiative of the European Community.
###end p 123

